

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE PROMOTION LICENSE OF “RABIES VIRUS PASSIVE
IMMUNE PREPARATION FOR ADULTS” IN BEIJING

The board of directors of China Health Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that 北京佑康健業醫療器械有限公司 (Beijing Youkang Jianye Medical Equipment Co., Ltd.*) (“Beijing Youkang”), a non-wholly-owned subsidiary of the Company, entered into the “Olmotivirumab Injection (Xunke) Promotion Service Agreement” with 華北製藥集團新藥研究開發有限責任公司 (North China Pharmaceutical Group New Drug R&D Co., Ltd.*) (“NCPG”) on 6 March 2022, pursuant to which Beijing Youkang has been granted the exclusive promotion service license for “Olmitevirumab Injection” in Beijing for a period commencing on the date of the agreement to 31 December 2023, and shall assist NCPG in carrying out related promotion activities of the drug in Beijing, including but not limited to market research, market access, academic promotion and training, logistics distribution and customer feedback and information services, and other services required by the market. Beijing Youkang shall receive promotion service fees from NCPG with reference to the service activities and service standards provided.

“Olmotivirumab Injection (trade name: Xunke)” is the latest medical biological product independently developed by NCPG, which is used for passive immunization of adults exposed to rabies virus. It was approved by the National Medical Products Administration (Approval No.: Guoyaozhunzi (國藥准字): S20220003), and was approved for sale in Beijing on 1 March 2022.

Established in 2018, Beijing Youkang is currently engaged in the distribution business of medical devices and equipment in Beijing and Hebei Province. Its major customers are large-scale tertiary medical institutions in Beijing and surrounding areas. The exclusive promotion license for “Rabies Virus Passive Immune Preparation for Adults (Xunke)” in Beijing granted by NCPG lays the foundation for the Company to gain access to the vast vaccine market in mainland China.

ABOUT NCPG

NCPG, headquartered in Shijiazhuang City, the capital of Hebei Province, is the largest pharmaceutical enterprise in China. Its predecessor, North China Pharmaceutical Factory (華北製藥廠), was a key construction project during the “First Five-Year Plan” of China, which was started in June 1953, and was completed and put into operation in June 1958. It pioneered the history of mass production of antibiotics in China, and made significant contributions to the human health business, the development of the national pharmaceutical industry and ameliorating the shortage of medical services and supplies in China. In 1992, North China Pharmaceutical Co., Ltd. was established through reorganization, and was listed on the Shanghai Stock Exchange in 1994 (stock name: North China Pharmaceutical 600812). In January 1996, North China Pharmaceutical Factory was officially restructured into NCPG which is a state-owned enterprise.

By Order of the Board
China Health Group Limited
Zhang Fan
Chairman and Executive Director

Hong Kong, 8 April 2022

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.

* *For identification purpose only*